BIOCRYST PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $14.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $14.69M, a 31.04% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $16.03M, a 25.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $18.64M, a 8.09% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $21.30M, a 61.72% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $85.14M, a 30.15% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $65.41M, a 17.62% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $55.62M, a 24.42% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $44.70M, a 29.04% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.69M 10-Q · filed 2026-08-05 | $30.72M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $16.03M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $85.14M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $18.64M 10-Q · filed 2025-11-04 | $39.95M derived: sum of 2 quarters · filed 2026-08-05 | $61.32M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $21.30M 10-Q · filed 2026-08-05 | $42.67M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $21.37M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $65.41M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $17.25M 10-Q · filed 2025-11-04 | $30.42M derived: sum of 2 quarters · filed 2025-11-04 | $44.07M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $13.17M 10-Q · filed 2025-11-04 | $26.82M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $13.65M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $55.62M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $12.28M 10-Q · filed 2024-11-05 | $25.12M derived: sum of 2 quarters · filed 2024-11-05 | $39.13M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $12.84M 10-Q · filed 2024-11-05 | $26.85M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $14.01M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $44.70M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $9.95M 10-Q · filed 2023-11-08 | $19.82M derived: sum of 2 quarters · filed 2023-11-08 | $29.42M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $9.87M 10-Q · filed 2023-11-08 | $19.47M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $9.60M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $34.64M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $13.03M 10-Q · filed 2022-11-04 | $20.66M derived: sum of 2 quarters · filed 2022-11-04 | $26.14M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | $7.63M 10-Q · filed 2022-11-04 | $13.11M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $5.48M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $14.79M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $2.87M 10-Q · filed 2021-11-04 | $6.15M derived: sum of 2 quarters · filed 2021-11-04 | $8.91M derived: sum of 3 quarters · filed 2021-11-04 | |
| 2020-06-30 | $3.28M 10-Q · filed 2021-11-04 | $6.03M derived: sum of 2 quarters · filed 2021-11-04 | ||
| 2020-03-31 | $2.75M 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $17.72M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $5.33M 10-Q · filed 2020-11-06 | $10.71M derived: sum of 2 quarters · filed 2020-11-06 | $14.03M derived: sum of 3 quarters · filed 2020-11-06 | |
| 2019-06-30 | $5.38M 10-Q · filed 2020-11-06 | $8.70M derived: sum of 2 quarters · filed 2020-11-06 | ||
| 2019-03-31 | $3.32M 10-Q · filed 2020-11-06 | |||
| 2018-12-31 | $9.40M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $2.08M 10-Q · filed 2019-11-08 | $4.17M derived: sum of 2 quarters · filed 2019-11-08 | $7.07M derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $2.08M 10-Q · filed 2019-11-08 | $4.99M derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $2.90M 10-Q · filed 2019-11-08 | |||
| 2017-12-31 | $12.62M 10-K · filed 2020-03-13 | |||
| 2016-12-31 | $8.49M 10-K · filed 2019-03-14 | |||
| 2015-12-31 | $9.71M 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $10.18M 10-K · filed 2017-02-27 | |||
| 2013-12-31 | $4.37M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $4.17M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $4.77M 10-K · filed 2014-03-10 | |||
| 2010-12-31 | $6.30M 10-K · filed 2013-03-11 | |||
| 2009-12-31 | $5.53M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |